These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20924131)

  • 1. Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.
    Kinders RJ; Hollingshead M; Lawrence S; Ji J; Tabb B; Bonner WM; Pommier Y; Rubinstein L; Evrard YA; Parchment RE; Tomaszewski J; Doroshow JH;
    Clin Cancer Res; 2010 Nov; 16(22):5447-57. PubMed ID: 20924131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.
    Pfister TD; Hollingshead M; Kinders RJ; Zhang Y; Evrard YA; Ji J; Khin SA; Borgel S; Stotler H; Carter J; Divelbiss R; Kummar S; Pommier Y; Parchment RE; Tomaszewski JE; Doroshow JH
    PLoS One; 2012; 7(12):e50494. PubMed ID: 23284638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.
    Kummar S; Chen A; Gutierrez M; Pfister TD; Wang L; Redon C; Bonner WM; Yutzy W; Zhang Y; Kinders RJ; Ji J; Allen D; Covey JM; Eiseman JL; Holleran JL; Beumer JH; Rubinstein L; Collins J; Tomaszewski J; Parchment R; Pommier Y; Doroshow JH
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):73-81. PubMed ID: 27169793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.
    Pommier Y; Cushman M
    Mol Cancer Ther; 2009 May; 8(5):1008-14. PubMed ID: 19383846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
    Burton JH; Mazcko C; LeBlanc A; Covey JM; Ji J; Kinders RJ; Parchment RE; Khanna C; Paoloni M; Lana S; Weishaar K; London C; Kisseberth W; Krick E; Vail D; Childress M; Bryan JN; Barber L; Ehrhart EJ; Kent M; Fan T; Kow K; Northup N; Wilson-Robles H; Tomaszewski J; Holleran JL; Muzzio M; Eiseman J; Beumer JH; Doroshow JH; Pommier Y
    Clin Cancer Res; 2018 Dec; 24(23):5830-5840. PubMed ID: 30061364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
    Jossé R; Martin SE; Guha R; Ormanoglu P; Pfister TD; Reaper PM; Barnes CS; Jones J; Charlton P; Pollard JR; Morris J; Doroshow JH; Pommier Y
    Cancer Res; 2014 Dec; 74(23):6968-79. PubMed ID: 25269479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2.
    Marzi L; Sun Y; Huang SN; James A; Difilippantonio S; Pommier Y
    Mol Cancer Ther; 2020 Aug; 19(8):1589-1597. PubMed ID: 32430490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA damage induced by DNA topoisomerase I- and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle phase and apoptosis.
    Huang X; Traganos F; Darzynkiewicz Z
    Cell Cycle; 2003; 2(6):614-9. PubMed ID: 14504478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin.
    Huang X; Okafuji M; Traganos F; Luther E; Holden E; Darzynkiewicz Z
    Cytometry A; 2004 Apr; 58(2):99-110. PubMed ID: 15057963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes.
    Furuta T; Takemura H; Liao ZY; Aune GJ; Redon C; Sedelnikova OA; Pilch DR; Rogakou EP; Celeste A; Chen HT; Nussenzweig A; Aladjem MI; Bonner WM; Pommier Y
    J Biol Chem; 2003 May; 278(22):20303-12. PubMed ID: 12660252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant
    Lee HM; Clark EP; Kuijer MB; Cushman M; Pommier Y; Philpot BD
    Mol Autism; 2018; 9():45. PubMed ID: 30140420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATM activation and histone H2AX phosphorylation as indicators of DNA damage by DNA topoisomerase I inhibitor topotecan and during apoptosis.
    Tanaka T; Kurose A; Huang X; Dai W; Darzynkiewicz Z
    Cell Prolif; 2006 Feb; 39(1):49-60. PubMed ID: 16426422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors.
    Marzi L; Agama K; Murai J; Difilippantonio S; James A; Peer CJ; Figg WD; Beck D; Elsayed MSA; Cushman M; Pommier Y
    Mol Cancer Ther; 2018 Aug; 17(8):1694-1704. PubMed ID: 29748210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluations of novel indenoisoquinolines as topoisomerase I inhibitors.
    Zhang X; Wang R; Zhao L; Lu N; Wang J; You Q; Li Z; Guo Q
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1276-81. PubMed ID: 22079759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.
    Antony S; Agama KK; Miao ZH; Takagi K; Wright MH; Robles AI; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
    Cancer Res; 2007 Nov; 67(21):10397-405. PubMed ID: 17974983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons.
    Beck DE; Lv W; Abdelmalak M; Plescia CB; Agama K; Marchand C; Pommier Y; Cushman M
    Bioorg Med Chem; 2016 Apr; 24(7):1469-79. PubMed ID: 26906474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitation of gammaH2AX foci in tissue samples.
    Tang MM; Mah LJ; Vasireddy RS; Georgiadis GT; El-Osta A; Royce SG; Karagiannis TC
    J Vis Exp; 2010 Jun; (40):. PubMed ID: 20613712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis.
    Dull AB; Wilsker D; Hollingshead M; Mazcko C; Annunziata CM; LeBlanc AK; Doroshow JH; Kinders RJ; Parchment RE
    Oncotarget; 2018 Mar; 9(24):17104-17116. PubMed ID: 29682208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
    Christmann M; Tomicic MT; Gestrich C; Roos WP; Bohr VA; Kaina B
    DNA Repair (Amst); 2008 Dec; 7(12):1999-2009. PubMed ID: 18805512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
    Tomicic MT; Kaina B
    Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.